Remicade - (100mg/vial; Injection)

Generic Name	Infliximab	Innovator	Janssen Pharma
Dosage	100mg/vial; Injection	Branded US Sales	More Than $1000 mn
Probable FTF	None	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	To reduce signs/symptoms, inhibit progression of structural damage, and improve physical function in psoriatic arthritis and with methotrexate in moderately to severely active rheumatoid arthritis (RA). To reduce signs/symptoms of active ankylosing spondylitis
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********(******)			*** ** ** ** '*** ******	******** ** *********	******** ** *** **, ****
******* *******			*******	******** ** *********	******** ** **** **, ****

Chronology Of Events